Mesoblast Limited (MESO)
The price, the headline numbers and the latest news, in one place.
Mesoblast Limited (MESO) Stock Price, Analysis & Data
| Bid | 12.41 |
| Market Cap | 2.25B |
| Revenue (ttm) | 120M |
| Net Income (ttm) | -57.5M |
| 0.81 | |
| -0.44 | |
| n/a | |
| 38 | |
| P/B (ttm) | 3.88 |
| P/S (ttm) | 18.67 |
| Earnings Date | Feb 25, 2027 |
| Ask | 22.05 |
| Volume | 296,624 |
| Avg. Volume (20D) | 226,392 |
| Open | 16.98 |
| Previous Close | 16.50 |
| Day's Range | 16.98 - 17.40 |
| 52-Week Range | 12.66 - 21.50 |
| Analyst | Buy |
| Price Target | 37 (114%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About MESO
Mesoblast Limited, together with its subsidiaries, engages in the development of regenerative medicine products in Australia. The company's proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. It offers remestemcel-L-rknd, which is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, Duchenn...
Financial Performance
In 2026, Mesoblast's revenue was 120.25M, an increase of 599.21% compared to the previous year's 17.2M. Earnings were -57.5M, a decrease of -43.71%.
Financial StatementsAnalyst Forecast
According to 2 analyst ratings, the average rating for MESO stock is "Buy". The 12-month stock price forecast is 37, which is upside of 114% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of n/a misses estimates by $0, with NaN% YoY growth.
- EPS of -0.29 exceeds estimates by 0.01, with 12.12% YoY growth.
Analysts project revenue of ... Upgrade
